Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Leucovorin 4venetoclax 3Specimen Handling 3Fluorouracil 3Doxorubicin 3Cytarabine 3Cyclophosphamide 3Bevacizumab 3trametinib 2pembrolizumab 2dabrafenib 2Taxes 2Sorafenib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-2 2Gemcitabine 2Daunorubicin 2Carboplatin 2Bortezomib 2Biopsy 2Azacitidine 2Albumin-Bound Paclitaxel 2vactosertib 1temsirolimus 1ruxolitinib 1romidepsin 1regorafenib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × bintrafusp alfa protein, human × Other hematologic neoplasm × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡